Valore202020212022202320242025TTMSpese di vendita, generali e amministrative11.11 M13.64 M17.3 M22.11 M29.55 M43.53 M43.53 MRicerca e sviluppo11.2 M13.78 M18.58 M17.5 M13.87 M29.25 M29.25 MReddito operativo-21.3 M-24.53 M-33.85 M-38.18 M-12.41 M660 K660 KProventi non operativi, Totale154 K68 K30 K92 K557 K1.63 M1.63 MOneri finanziari, al netto degli interessi capitalizzati0675 K1.9 M————Proventi non operativi, esclusi gli oneri finanziari0-675 K-1.9 M151 K587 K1.7 M1.7 MEntrate/uscite straordinarie154 K68 K30 K-59 K-30 K-70 K-70 KUtile al lordo delle imposte-24.16 M-25.65 M-36.51 M-47.68 M-26.39 M3.51 M3.51 MQuota di utile———————Imposte00000810 K813 KInteressi di minoranza24.21 M——————Altri proventi/oneri al netto delle imposte———————Utile netto al lordo delle attività cessate-24.16 M-25.65 M-36.51 M-47.68 M-26.39 M2.7 M2.7 MAttività cessate———————Utile netto-24.16 M-25.65 M-36.51 M-47.68 M-26.39 M2.7 M2.7 MRegolazione della diluizione———————Dividendi privilegiati———————Utile netto diluito attribuibile agli azionisti ordinari-24.16 M-25.65 M-36.51 M-47.68 M-26.39 M2.7 M2.7 MUtile base per azione (EPS base)-8.35—-4.12-2.94-0.930.080.08Utile diluito per azione (EPS diluito)-8.35—-4.12-2.94-0.930.070.07Numero medio di azioni ordinarie in circolazione2.9 M—8.86 M16.23 M28.51 M35.82 M142.63 MAzioni diluite in circolazione2.9 M—8.86 M16.23 M28.51 M39.92 M159.75 MEBITDA-22.58 M-28.16 M-34.85 M-37.28 M-11.82 M898 K898 KEBIT-22.74 M-28.63 M-35.75 M-38.18 M-12.41 M660 K660 KCosto del fatturato640 K671 K686 K635 K6.19 M11.8 M11.8 MAltri costi del venduto———————Ammortamento e svalutazione (liquidità)167 K469 K900 K904 K594 K238 K238 K
Delcath Systems Inc
Delcath Systems, Inc. is a publicly traded specialty pharmaceutical and medical device company, that develops percutaneous perfusion technologies for the targeted administration of high-dose chemotherapeutic agents to specific organs or regions of the body. Based in Queensbury, New York, the company has an intellectual property portfolio consisting of 28 patents worldwide. Delcath's Percutaneous Hepatic Perfusion is currently undergoing Phase II and Phase III trials against tumors in the liver. Delcath has a Cooperative Research and Development Agreement with the National Cancer Institute and has received Fast Track and a Special Protocol Assessment from the Food and Drug Administration for its use of melphalan in treating unresectable liver tumors. PHP, also known as the Delcath System, is tested for the treatment of metastatic melanoma in the liver and for primary liver cancer and metastatic hepatic malignancies from neuroendocrine cancers and adenocarcinomas, as well as patients with melanoma who previously received isolated perfusion. Chemotherapy is usually delivered intravenously, although a number of agents can be administered orally.